The Clinical Benefit of Ruxolitinib Across Patient Subgroups: Analysis of a Placebo-Controlled, Phase III Study in Patients With Myelofibrosis

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.12274

Related search